ABOUT THE PROGRAM
The
annual Pharmacogenetics in Psychiatry meeting has provided a forum for
the presentation and discussion of new developments in the rapidly
developing field of psychiatric pharmacogenetics. Previous meetings have
been highlighted by discussion of topics including: prediction of
clinical response to antipsychotic drugs, genes associated with the
development of adverse side effects, candidate gene and genome-wide
association (GWAS) studies of antidepressant response, the
identification of new polymorphisms influencing gene product function,
and novel statistical approaches to dissect the heterogeneity of drug
response. Moreover, we have brought together investigators working in
diverse areas of psychiatric research, from molecular geneticists to
clinical trial investigators, from academia and industry, in order to
engender true interdisciplinary approaches to the problem of variation
in clinical response to psychotropic drugs. It is our hope that each
participant will come away from this meeting with an appreciation of the
breadth of this emerging field.
We would like to thank our
financial supporters. These include the Feinstein Institute for Medical
Research, the National Institute of Mental Health, and industry
partners. Funding for this conference was made possible (in part) by
(R13 MH090652) from the National Institute of Mental Health. The views
expressed in written conference materials or publications and by
speakers and moderators do not necessarily reflect the official policies
of the Department of Health and Human Services; nor does mention by
trade names, commercial practices, or organizations imply endorsement by
the U.S. Government.
|
|
